98-28901. Food Labeling: Warning and Notice Statement; Labeling of Juice Products; Technical Scientific Workshops; Requests for Additional Time to Achieve the Pathogen Reduction Standard  

  • [Federal Register Volume 63, Number 208 (Wednesday, October 28, 1998)]
    [Rules and Regulations]
    [Pages 57594-57596]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-28901]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 101
    
    [Docket No. 97N-0524]
    
    
    Food Labeling: Warning and Notice Statement; Labeling of Juice 
    Products; Technical Scientific Workshops; Requests for Additional Time 
    to Achieve the Pathogen Reduction Standard
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Technical scientific workshops; requests for additional time to 
    achieve the pathogen reduction standard; rule related.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing two 
    technical scientific workshops to discuss and clarify issues related to 
    the implementation of the agency's rule requiring a warning statement 
    for certain juice products. In particular, the workshops will address 
    the pathogen reduction interventions that have been developed for 
    citrus juice production and the methods for measuring and validating 
    such systems. FDA is also announcing a process by which individual 
    manufacturers of citrus juices may request additional time, beyond the 
    current compliance date of November 5, 1998, to implement a validated 
    system of control measures that achieves the required reduction in 
    pathogenic microorganisms. Manufacturers who implement such control 
    measures will not be required to use the warning statement on their 
    juice products. These actions are being taken in response to requests 
    from several fresh citrus juice manufacturers that have indicated they 
    want to implement improved controls but need additional time to do so.
    
    DATES: The technical scientific workshops will be held on November 12, 
    1998, and on November 19, 1998. Both workshops will be from 8:30 a.m. 
    to 5:30 p.m. Registration for the workshops will be provided on a first 
    come, first served basis and must be received by November 6, 1998.
        Individual fresh citrus juice producers may request additional time 
    to comply with the pathogen reduction standard in Sec. 101.17(g)(7)(i) 
    (21 CFR 101.17(g)(7)(i)) until December 19, 1998. For requests for 
    additional time, see the FDA District Directors listed under the 
    SUPPLEMENTARY INFORMATION section of this document.
    ADDRESSES: The technical scientific workshops will be held at the 
    following locations:
        The November 12, 1998, workshop will be held at the Citrus Research 
    and Education Center, University of Florida, Lake Alfred, FL 33850, 
    941-956-1151 and
         the November 19, 1998, workshop will be held at the FDA District 
    Office, 19900 MacArthur Blvd., suite 300, Irvine, CA 90015-2486, 949-
    252-7592.
        For requests for additional time, see the FDA District Directors 
    listed under the SUPPLEMENTARY INFORMATION section of this document.
    FOR FURTHER INFORMATION CONTACT:
        To register for a technical workshop, please contact Catherine M. 
    DeRoever, Center for Food Safety and Applied Nutrition (CFSAN) (HFS-
    22), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 
    202-205-4251, FAX 202-205-4970 or e-mail cderoeve@bangate.fda.gov''. 
    Registration information (including name, title, firm name, address, 
    telephone and fax numbers) must be received no later than November 6, 
    1998.
        For information on requests for additional time to achieve the 
    pathogen reduction standard, please contact, as listed in the 
    SUPPLEMENTARY INFORMATION section of this document, the Director of the 
    FDA District Office in which the firm is located.
        If you need special accommodations due to a disability, please 
    contact Catherine M. DeRoever at the previous address at least 7 days 
    in advance.
        Interested persons should note that additional information 
    regarding the technical scientific workshops, making requests for 
    additional time and other relevant information will be posted on 
    CFSAN's web site, ``www.cfsan.fda.gov,'' as it becomes available. 
    Accordingly, such persons may wish to visit that web site on a regular 
    basis until the workshop convenes.
    SUPPLEMENTARY INFORMATION: Requests by individual citrus firms for 
    additional time to implement control measures and validate that the 
    process achieves the pathogen reduction in Sec. 101.17(g)(7)(i) should 
    be addressed to the Director of the FDA District in which the firm is 
    located. For firms in Florida, Texas, Arizona, and California the 
    addresses are:
        Douglas Tolen, District Director, FDA Florida District Office, 7200 
    Lake Ellenor Dr., suite 120, Orlando, FL 32809, 407-475-4700;
    
    [[Page 57595]]
    
        Joseph Baca, District Director, FDA Dallas District Office, 3310 
    Live Oak St., Dallas, TX 75204, 214-655-5315; or
        Elaine C. Messa, District Director, FDA Los Angeles District 
    Office, 19900 MacArthur Blvd., suite 300, Irvine, CA 92612-2445, 949-
    798-7714.
         In the Federal Register of July 8, 1998 (63 FR 37030), FDA 
    published a final regulation that requires a warning statement on fruit 
    and vegetable juice products that have not been processed to prevent, 
    reduce, or eliminate pathogenic microorganisms that may be present in 
    such juices. The regulation provides that the warning statement 
    requirement does not apply to a juice that has been processed in a 
    manner that will produce, at a minimum, a reduction in the pertinent 
    microorganism of at least a 5-log magnitude (i.e., 100,000 fold). In 
    the preamble to the proposed rule (63 FR 20486, April 24, 1998), FDA 
    recognized that pasteurization is a process that can produce the 5-log 
    reduction. The agency also noted that manufacturers may be able to use 
    other technologies and practices, individually or in combination (such 
    as a combination of eliminating use of drops, brushing, washing and 
    using sanitizers) to achieve the 5-log reduction, provided that the 
    manufacturer's process is validated to achieve the 5-log reduction in 
    the target microorganism.
        In the preamble to the final regulation, FDA stated its expectation 
    that citrus juice processors should be able to achieve and validate a 
    5-log reduction without pasteurization (63 FR 37030 at 37042). FDA also 
    indicated that it would be willing to meet with manufacturers or groups 
    of manufacturers to discuss and evaluate their proposed processes. In 
    addition, FDA stated that in order to help processors meet the pathogen 
    reduction standard, the agency would make available, in accordance with 
    21 CFR part 20 of its regulations, information received by the agency 
    regarding processes that have been validated to achieve a 5-log 
    reduction.
        FDA has received requests from several manufacturers of fresh 
    citrus juice for 18-additional months beyond the November 5, 1998, 
    compliance date for the warning statement requirement to permit such 
    firms to develop and to validate procedures that will achieve the 5-log 
    reduction in citrus juices. In discussions with the agency, there was 
    evidence of widespread confusion among juice manufacturers as to how 
    FDA expects the 5-log reduction to be achieved.
        Upon consideration of the fresh citrus juice manufacturers' request 
    and in light of other information before the agency regarding progress 
    made by some citrus juice manufacturers in identifying effective 
    mechanisms for pathogen reduction, FDA has developed a two-part 
    strategy to respond to these requests. First, FDA will sponsor two 
    technical scientific workshops for the citrus juice industry, open to 
    the public, on November 12 and November 19, l998. Each workshop will 
    include a discussion of the control measures of which FDA is aware that 
    are being used for citrus juice production and of the methods for 
    measuring and validating the effectiveness of the measures in reducing 
    pathogens. FDA believes that these workshops will provide an 
    opportunity for industry representatives and other members of the 
    public to share information regarding control measures that are 
    believed to achieve the 5-log reduction. Participants are requested to 
    bring to the workshop at least 150 copies of any written or published 
    materials they wish to distribute at the workshop. Agency experts will 
    be available to answer technical questions.
        Second, as noted, several firms have requested that FDA extend the 
    final rule's compliance date for citrus juices to permit those firms 
    additional time to develop and validate intervention measures that 
    achieve the 5-log pathogen reduction standard. FDA believes that a 
    formal extension of the rule's compliance date is not feasible in the 
    current circumstances because such extension would arguably require 
    notice and comment rulemaking. Nevertheless, FDA believes that under 
    certain conditions (which are enumerated as follows), it would be an 
    appropriate exercise of the agency's enforcement discretion to suspend 
    enforcement of the final rule for a limited period of time. In 
    particular, FDA will consider such an exercise of its enforcement 
    discretion for those citrus juice producers who no later than December 
    19, 1998, request such consideration and who make the following 
    commitments in writing:
        (1) The firm agrees to use the time period between November 4, 
    1998, and July 8, 1999, to develop, adapt, and validate procedures that 
    are sufficient to achieve a 5-log reduction in the pertinent 
    microorganism; and,
        (2) The firm agrees to establish interim protection measures in the 
    form of a system that applies hazard analysis and critical control 
    point (HACCP) principles. This interim system will include, at a 
    minimum, good manufacturing practices and specific control measures 
    such as chemical washing and brushing of the fruit, sanitizing, culling 
    of damaged fruit, and utilization of only those types of fruit with 
    skins that are sufficiently smooth and durable to be cleanable and to 
    remain intact after cleaning; and,
        (3) The firm agrees to comply with the provisions of the warning 
    label regulation (Sec. 101.17 (g)) no later than July 8, 1999. As a 
    result of this commitment, the firm will use the warning label on its 
    products beginning July 8, 1999, if it has been unable to implement 
    validated control measures that achieve the 5-log reduction.
        FDA believes that this two-part strategy is reasonable and will 
    provide appropriate public health protection. As noted in the warning 
    statement rulemaking, because the warning statement provides consumers 
    with important information about the risk of foodborne illness, the 
    warning requirement contributes to public health protection in that it 
    allows consumers to make informed purchase decisions. In FDA's view, 
    this warning statement requirement is primarily an interim step 
    designed to reduce the risk of fresh juice consumption pending 
    completion of a final HACCP rule and its implementation. However, 
    because the warning statement requirement may nevertheless allow 
    contaminated juice products to reach the marketplace, FDA does not 
    expect the statement to be as effective in protecting consumers as 
    would a validated 5-log reduction program. FDA believes it is 
    appropriate to consider exercising its enforcement discretion where, as 
    a result of such exercise, the agency can provide an incentive for 
    citrus juice processing firms to produce safe juice earlier than such 
    firms would otherwise do.
        Because of the relationship between particular provisions in the 
    warning statement regulation and the HACCP proposal, FDA is announcing 
    its intention to reopen the comment period on the juice HACCP proposal 
    (63 FR 20450) entitled ``Hazard Analysis and Critical Control Point 
    (HACCP); Procedures for the Safe and Sanitary Processing and Importing 
    of Juice.'' This reopening will allow information and data presented at 
    the workshop to be included in the record of the HACCP rulemaking. A 
    Federal Register document announcing the reopening of the juice HACCP 
    proposal comment period will be published at a later date.
        Transcripts of the workshops will be prepared. Copies of the 
    transcripts may be requested in writing from the Freedom of Information 
    Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 
    12A-16, Rockville, MD 20857, approximately 15-working
    
    [[Page 57596]]
    
    days after the meetings at a cost of 10 cents per page.
    
        Dated: October 23, 1998.
     William B. Schultz,
     Deputy Commissioner for Policy.
    [FR Doc. 98-28901 Filed 10-23-98; 3:47 pm]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
10/28/1998
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Technical scientific workshops; requests for additional time to achieve the pathogen reduction standard; rule related.
Document Number:
98-28901
Dates:
The technical scientific workshops will be held on November 12, 1998, and on November 19, 1998. Both workshops will be from 8:30 a.m. to 5:30 p.m. Registration for the workshops will be provided on a first come, first served basis and must be received by November 6, 1998.
Pages:
57594-57596 (3 pages)
Docket Numbers:
Docket No. 97N-0524
PDF File:
98-28901.pdf
CFR: (1)
21 CFR 101